Two consecutive, open, prospective trials of intermittent azithromycin (600 mg), usually given Monday, Wednesday, and Friday (TIW) for Mycobacterium avium complex (MAC) lung disease were initiated in human immunodeficiency virus -negative patients. Regimen A consisted of TIW azithromycin and daily ethambutol (15 mg/kg/day), daily rifabutin (300 mg/day), and initial twice weekly (BIW) streptomycin. Regimen B consisted of TIW azithromycin, TIW ethambutol (25 mg/ kg/dose), TIW rifabutin (600 mg/dose), and initial BIW streptomycin. Of 19 patients enrolled in regimen A who completed at least 6 months of therapy, 14 (74%) had sputum samples become culture-negative. Of 39 patients enrolled in regimen B who completed at least 6 months of therapy, 24 (62%) had sputum conversion. These sputum conversion rates are comparable to previous rates at 6 months in patients receiving daily clarithromycin-or azithromycin-containing regimens. No resistance to azithromycin emerged with either regimen. This is the first study to demonstrate the efficacy of intermittent administration of medication for MAC lung disease.
. Features of the azithromycin suggest that it also would be effective in an interpretreatment chest radiograph, history of prior antituberculous drug therapy, records of prior AFB smear and culture results, and patient demographic information were recorded. Patients were considered Received 3 October 1997; revised 9 February 1998. to have received prior therapy if they received §6 months of ability for long-term follow-up. Patients could be hospital inpa- were considered improvement without sputum conversion, patients received companion drugs in one of two regimens. Patients whereas no change in colony counts was considered as no rewere recruited first to regimen A and then consecutively (not ransponse. The percentage of patients in each of these categories at domized) to regimen B (results with regimen A were sufficiently 6 months was recorded. encouraging that regimen B was instituted).
Susceptibility testing. A pretreatment isolate of MAC and seRegimen A consisted of 25 mg/kg/day ethambutol for 2 months lected isolates from patients receiving treatment were subcultured followed by 15 mg/kg/day ethambutol, 300 mg/day rifabutin, and on 7H10 agar. Clarithromycin (and usually azithromycin) MICs streptomycin, usually included for the first 2 months of therapy, were then performed, using broth microdilution with 2-fold drug given two to three times weekly with dosage adjusted for age and dilutions in Mueller-Hinton broth supplemented with 5% oleic weight (500-1000 mg).
acid-albumin and dextrose. At pH 7.4, plates were incubated for Regimen B consisted of all oral drugs in the regimen adminis-2 weeks in room air, as previously described [13, 14] . Isolates tered on a TIW basis, including 25 mg/kg ethambutol and 300-were considered to be macrolide-susceptible if the MIC for clar-600 mg of rifabutin (dosage based on patient body weight). Strepithromycin was £8 mg/mL and macrolide-resistant if the MIC was tomycin was also usually included for the first 2 months of therapy §32 mg/mL. A MIC of 16 mg/mL was considered intermediate. and was given two to three times per week, with dosage adjusted Each isolate was frozen at 070ЊC for future needs. for age and weight (500-1000 mg). The results for the first 6 Drug tolerance and safety tests. Patients were questioned months of therapy with each regimen are reported.
about problems and symptoms (especially gastrointestinal, audi-AFB smears and cultures. Generally, 3 daily sputum specitory, and vestibular) at baseline and at each clinic visit, both vermens were collected at entrance into the study, and at least 1 bally and by use of a written questionnaire. In addition, a study specimen was collected every 4 weeks during therapy. Sputum coordinator was available 5 days per week by telephone. Laborasamples were decontaminated with N-acetyl-L-cysteine sodium hytory safety tests measured baseline liver enzymes (including a droxide (NALC/NaOH) using routine methods [12] . Semiquantitaglutamyl transpeptidase and alkaline phosphatase), blood urea nitive AFB smears (fluorochrome method) were performed at magnitrogen, serum creatinine, and complete blood cell count. The liver fication 1200 as previously described [2] . Cultures on enzymes and complete blood cell count were retested monthly for Middlebrook 7H10 agar were quantitated from no growth to 4/, 6 months. Liver enzymes were considered to be increased if the using published standards and as previously described [2] . For enzymes rose during therapy to twice the upper limits of normal patients whose initial sputum specimens were contaminated (espe-(if baseline values were normal) or to twice the baseline value if cially by Pseudomonas aeruginosa), subsequent samples were prothey were already abnormal. Routine audiograms were also percessed initially with NALC/NaOH and then processed a second formed at baseline for the first 31 patients. Audiograms were pertime with oxalic acid [12] . In addition, samples were also inocuformed during therapy upon any subjective decrease in auditory acuity for all patients enrolled in the study. lated onto a 7H10 agar plate containing 10 mg/mL tobramycin.
Statistical analysis.
Group results are expressed as means { SD. Comparison of patient characteristics between treatment groups, intermittent azithromycin regimen A or regimen B, and previous daily azithromycin and clarithromycin regimens was done using an unpaired t test with a two-tailed P value. Comparison of culture results in responders and nonresponders before and at the end of therapy and comparison with previous azithromycin and clarithromycin treatment groups at 6 months were done using a x 2 analysis and Fisher's exact test with Yates's correction for small sample sizes. Significance was determined at P £.05.
Results
Regimen A. Twenty-one patients were enrolled in regimen A; 19 completed at least 6 months of therapy. Four (21%) had received ú6 months of therapy previously, with or without a macrolide. Eight (42%) of these 19 were women (mean age, 66.1 { 11.8 years), and 11 (58%) were men (mean age, 62.8 { 16.2 years). Two patients were dropped prior to completion of 6 months of therapy, 1 because of noncompliance and 1 because of gastrointestinal symptoms (primarily diarrhea). Of the women, 33% were current or former smokers (ú20 pack years), and 90% of the men were current or former smokers.
Fourteen (74%) of 19 patients had their sputum culture convert to negative within the first 6 months of therapy (mean time to sputum conversion, 4.4 { 1.6 months). One patient also had a right upper lobectomy. Three patients (16%) had microbiologic improvement in their sputum cultures without conversion to negative. These 6 patients also had symptomatic improvement. Overall, 17 (89%) of 19 patients had either sputum culture conversion or improvement. Two patients had neither symptomatic improvement nor improvement of sputum AFB cultures.
In general, the TIW 600-mg dose of azithromycin was well tolerated in regimen A and was reduced to 300 mg in only 4 patients, primarily because of loose stools. All but the 2 patients without improvement in sputum cultures who received regimen A had symptomatic improvement while receiving protocol medications. Comparison of these results at 6 months with other macrolide-containing regimens for the treatment of pulmonary MAC disease is shown in table 1.
Regimen B. Forty-seven patients were enrolled in regimen B, the TIW multidrug regimen. The following 8 patients received õ6 months of medication: 3 men, due to noncompliance; 1 woman, due to death unrelated to MAC disease; and 4 (3 men and 1 woman) due to intolerable gastrointestinal symptoms (primarily diarrhea). The remaining 39 patients received at least 6 months of medication. Nine (23%) had received ú6 months of therapy previously, with or without a figure 1 shows radiographic findings). Three of these patients also had surgical resection of severely affected lung tissue, including two right pneumonectomies and one right upper lobectomy ( figure 2 ). An additional 6 patients (15%) met criteria for improvement as indicated by improvement in sputum cultures. Overall, 30 (77%) of 39 patients either had their sputum become culturenegative or had improvement in sputum culture results within the first 6 months of therapy with this regimen. Regimen B is compared with regimen A and with previous macrolidecontaining regimens in table 1. Of 39 patients, 9 (23%) had no change in their sputum culture results within the first 6 months of therapy. These patients included 4 men (ages 53.4 { 14.1 years), 75% of whom were current or former smokers, and 5 women (ages 76.8 { 11.4 years), 20% of whom were current or former smokers.
Regimens A and B. There were no significant differences in patient characteristics between regimens A and B. Similarly, there were no significant differences in patient characteristics between either intermittent azithromycin regimen A or regimen B and the patients who previously received daily clarithromycin or azithromycin regimens (data not shown) [1, 2] .
All patients had clarithromycin-susceptible MAC isolates at the beginning of therapy. Thirteen patients were considered to have had significant prior drug therapy, with or without a macrolide, prior to entry into either intermittent azithromycin protocol. Sputum conversion occurred in 5 (46%) of 13 (2/4 from regimen A, 3/9 from regimen B) patients with previous therapy versus 33 (73%) of 45 (12/15 from regimen A, 21/30 from regimen B) patients without previous therapy (P Å .04).
Six patients (2 from regimen A, 4 from regimen B; 3 women, 3 men) required a decrease in azithromycin dosage to 300 mg TIW, 3 on the basis of intolerable gastrointestinal symptoms (abdominal bloating, diarrhea, and/or nausea) and 3 on the basis of decreased auditory acuity and/or tinnitus. Symptoms resolved in all patients with the decrease in azithromycin dosage. On retesting, no patient on either of the intermittent multidrug regimens (azithromycin dose of 300 mg or 600 mg) had emergence of a macrolide-resistant MAC isolate.
Discussion
This is the first multidrug treatment trial for either pulmonary or disseminated MAC infection to utilize intermittent therapy. This study demonstrates that multidrug regimens including understandably be directed toward tuberculosis. More and more, the cost of treatment for MAC disease will fall to the azithromycin, given intermittently, can be effective for converting sputum to culture negativity in patients with pulmonary individual. Minimizing cost will be imperative to make these treatment regimens a realistic option for people with pulmonary MAC disease. The overall sputum conversion rate at 6 months in this study was 71% for regimen A and 62% for regimen B, MAC disease. Patient compliance would also likely improve with intermitboth similar to our findings in two previous studies involving 4 months of daily single-drug therapy (followed by 2 months tent drug administration. Alcoholism is a major risk factor for the upper lobe fibrocavitary (tuberculosis) type of MAC disease of the same daily multiple drugs) utilized in these trials with either clarithromycin (74% sputum conversion rate) or azithroand almost certainly increases the incidence of noncompliance. For some patients whose therapy is failing for unclear reasons, mycin (58% sputum conversion rate). The current intermittent regimen was generally well tolerated with only a small percentintermittent administration will allow directly observed therapy to eliminate noncompliance as a mechanism of treatment failage (14%) of patients requiring azithromycin dosage adjustment and no patients requiring discontinuation of therapy beure. These benefits of intermittent therapy have long been recognized in the treatment of tuberculosis. Intermittent medicacause of an azithromycin-related adverse event.
Although all patients had clarithromycin-susceptible isolates tion administration also lowers the required total weekly dose of both azithromycin and rifabutin, which will decrease the at entry into the study, 11% of patients in regimen A and 24% of patients in regimen B had no microbiologic improvement adverse events associated with chronic administration of these medications, another important factor in patient compliance during 6 months of therapy. Treatment failures were equally divided between men and women and appeared to mirror the [15, 16] . It is also possible that intermittent therapy with an azithrodemographics of the study patient population as a whole, including age and smoking status. Because none of these patients mycin-containing regimen will have utility for treatment of disseminated MAC disease. Azithromycin given once weekly received their medications by directly observed therapy, noncompliance with the treatment regimen cannot be excluded as is effective as prophylaxis against disseminated MAC infection [6] , and the advantages listed above for intermittent therapy of the cause of the treatment failure, although it seems an unlikely explanation in all cases. These patients tended to have severe pulmonary MAC disease are all pertinent for disseminated MAC disease as well [6] . disease; however, significant differences between those with treatment failures and responders in this regard are difficult to Because of long half-life and concentration in phagocytes and tissues, azithromycin would appear to be an almost ideal quantitate. Those with treatment failures did have a higher incidence of previous macrolide therapy that did not impact in agent for long-term intermittent administration of chronic infections such as mycobacterial diseases. When given daily, vitro MAC susceptibility to macrolide but may be an indication that some of these patients have an as yet unidentified factor azithromycin appears to have early (first 6 months) activity comparable to that of clarithromycin against pulmonary MAC that defeats treatment with even good drug regimens. In support of this concept, only 5 (38%) of 13 patients from both treatment disease [1] . It remains to be seen if azithromycin will be as effective as clarithromycin in multidrug regimens given over protocols who had significant prior therapy had sputum conversion, whereas 33 (73%) of 45 patients without previous therapy long periods of time. had sputum conversion, a difference that was statistically significant. In all of our MAC treatment trials, we have found
